Research Article

Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma

Yinghong Zhou,1,2 Xiaofeng Dong,3 Peng Xiu,1 Xin Wang,4 Jianrong Yang,1,3 Lei Li,2 Zhongchao Li,2 Pengfei Sun,2 Xuetao Shi,2 and Jingtao Zhong2

1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250200, China
2Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
3Department of Hepatobiliary and Pancreatic Surgery Breast and Thyroid Surgery, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
4Department of Hepatobiliary Surgery, Shandong Provincial Qianfoshan Hospital, The First Hospital Affiliated with Shandong First Medical University, Jinan 250014, China

Correspondence should be addressed to Jingtao Zhong; jingtao2005@126.com

Received 19 January 2020; Accepted 2 March 2020; Published 24 March 2020

Academic Editor: Peeter Karihtala

Copyright © 2020 Yinghong Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However, the underlying mechanism remains to be elucidated in HCC, especially under hypoxic conditions. The alteration of COX-2 and HIF-1α oncogenicity was evaluated in HCC specimens by tissue microarray. Cell viability, angiogenesis assays, and xenografted nude mice were used to evaluate the effects of meloxicam, along with flow cytometry to detect the cell cycle, apoptosis, and mitochondrial membrane potential (ΔΨm) of HCC. qRT-PCR, Western blotting, immunofluorescence, immunohistochemistry, luciferase assay, and RNAi were carried out to determine the HIF-1α signaling affected by meloxicam. In this study, we showed that meloxicam exerts antiproliferative and antiangiogenesis efficacy in vitro and in vivo and causes disruption of mitochondrial membrane potential (ΔΨm), thus leading to caspase-dependent apoptosis under hypoxic environments. Exposure to meloxicam significantly reduced HIF-1α transcriptional activation and expression through sequestering it in the cytoplasm and accelerating degradation via increasing the von Hippel-Lindau tumor suppressor protein (pVHL) in HCC. These data demonstrated that inhibition of HIF-1α by meloxicam could suppress angiogenesis and enhance apoptosis of HCC cells. This discovery highlights that COX-2 specific inhibitors may be a promising therapy in the treatment of HCC.

1. Introduction

Hepatocellular carcinoma (HCC) ranks sixth among the most common carcinoma and is the fourth leading cause of cancer-related death worldwide [1]. Hepatitis virus infection (hepatitis B or C viruses), aflatoxins and aristolochic acid exposure, alcohol intake, and metabolic liver disease are considered the principal risk factors resulting in the development of HCC [2]. Surgical resection, orthotopic liver transplantation, and radiofrequency ablation are very effective therapeutic strategies in the early stage of HCC whereas most HCC patients are in an advanced stage of disease while diagnosed. Because the details of the molecular mechanisms of HCC progression are still unknown, there is currently a lack of effective systemic therapies, which causes the 5-year survival rate of advanced HCC to remain devastatingly low at 1% [3].
Consequently, there is an urgent need to better understand these mechanisms and develop new therapeutics for HCC treatment.

Hypoxia is an established characteristic of all solid tumors caused by aberrant vascularization and poor blood supply. In HCC, the degree of tumor hypoxia appears to be inversely related to the patient’s prognosis. Also, it is usually resistant to traditional treatment [4, 5]. Hypoxia-inducible factor- (HIF-) 1, a heterodimeric transcriptional factor composed of HIF-1α and HIF-1β/ARNT subunits, is the best studied among HIF-α subunits and has a crucial role in mediating gene expression in order to maintain oxygen homeostasis. The HIF-1α subunit is rapidly degraded under normoxic conditions through two ways: von Hippel-Lindau tumor suppressor (pVHL) and factor inhibiting HIF1 (FIH1) [6, 7]. However, when the oxygen concentration declines, expression of HIF-1α exponentially increases which allows it to dimerize with the HIF-1β subunit to form hypoxia response elements (HREs) regulating targeted genes involved in the process of tumoral angiogenesis, proliferation, metastasis, and apoptosis of cancer cells [8, 9].

Cyclooxygenases (COXs) are an enzyme that are responsible for the formation of prostaglandin (PG) through rate limiting with three isoforms: COX-1 [10], COX-2 [11], and COX-3 (a splice variant of COX-1) [12]. It is widely accepted that COX-2 has an important role in the stimulation of inflammation and tumorigenesis in hypoxic cancer cells [13, 14], and the COX-2-selective inhibitor has been considered a potential candidate which can disturb the angiogenic signaling cascade upstream of HIF-1α-VEGF expression [15–17]. Our previous studies also indicated that meloxicam, a selective inhibitor of COX-2, has antiproliferative and proapoptotic effects in HCC [18–20]. However, the detailed mechanisms of meloxicam for treating HCC have not been fully explored, especially under a hypoxic microenvironment. The main purpose of this study was to explore the potential of meloxicam as therapy in HCC and to test the hypothesis that its effect on cell proliferation, angiogenesis, and related pathways might be involved in the treatment of meloxicam-induced apoptosis under hypoxic conditions.

2. Materials and Methods

2.1. Clinical Samples and Animal Experimental Protocols. Tissue microarrays (TMAs) from 90 HCC patients undergoing immunohistochemistry (HHLivH180Su18) were obtained from Outdo Biotech Co., Ltd. (Shanghai, China). Ethical evidence provided by the company confirmed the consent procedures approved by the local ethics committee. The ethical statement and experiment protocol were approved by the institutional research ethics committee of Shandong Cancer Hospital and Institute. Expressions of COX-2 and HIF-1α in TMAs were detected by immunohistochemistry (IHC). Survival time was calculated from the date of surgery to the end of the follow-up or the date of death.

All animal experimental protocols (SDTHEC-201912007) were carefully checked and approved by the institutional research ethics committee of Shandong Cancer Hospital and Institute, and the methods were described in our previous studies [5, 21]. Huh-7 and Hep3B cells (5 × 10^6/ml in PBS) were inoculated into the dorsal area near the front leg of 4-week-old BALB/c nude mice (10 mice per cell type) (HFK Bioscience Company, Beijing, China). The observation of mice continued until tumors developed to a size of 100 mm^3. Then, the mice were randomly divided into four groups (5 in each group) Two groups were mice inoculated with Huh-7 cells, and two groups were mice inoculated with Hep3B cells. The experimental groups were managed by intraperitoneal injection of meloxicam (30 mg/kg) diluted in PBS every two days, while the control group was managed by an identical volume of 0.9% normal saline (0.9% NS). The tumors were harvested at the end of the experiments.

2.2. Reagents and Cell Culture. Meloxicam was acquired from Merck Millipore (Darmstadt, Germany). Cyclooxygenase, Z-VAD-FMK, JC-1, and MG-132 were purchased from Sigma-Aldrich (San Diego, USA). Primary antibodies to HIF-1α, VEGFA, von Hippel-Lindau, PARP1, cleaved PARP1, Ki-67, CD31, and GAPDH were obtained from Abcam (Cambridge, UK). Primary antibodies to caspase-3, caspase-9, cleaved caspase-9, and histone H3 were obtained from Cell Signaling Technologies (Danvers, MA).

The 2 human HCC cell lines, Huh-7 and Hep3B, and the normal human liver cell line, L-02, were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and preserved in our laboratory. The cells were routinely cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco) and 1% antibiotics at 37°C in 95% air and 5% CO2. Human umbilical vein endothelial cells (HUVECs) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA). The cells were cultured in endothelial cell medium (ECM, ScienCell Research Laboratories) at 37°C in 95% air and 5% CO2. For the hypoxia experiments, Huh-7 and Hep3B cells were cultured in a hypoxic chamber (Billups-Rothenberg, Inc.) with 1% O2, 5% CO2, and 94% nitrogen.

2.3. Flow Cytometric Analysis of Cell Cycle, Apoptosis, and Mitochondrial Membrane Potential (ΔΨm). Cells (4 x 10^5/well) were seeded with culture medium in a 6-well plate, incubated at 37°C for 24 h, and then incubated with fresh medium with various concentrations of meloxicam (0 to 80 μM) combined with or without Z-VAD-FMK (50 μM) in a hypoxic chamber. After washing twice with cold PBS and resuspending with binding buffer, the ANXAS-FITC/PI Detection Kit (BD Biosciences, San Jose, CA) was used to analyze apoptotic cells and the cell cycle distribution by flow cytometry according to the manufacturer’s instruction. For JC-1 staining, cells were resuspended in PBS, containing 0.1 μM JC-1, and were incubated at 37°C for 15 min in the dark. Then, cells were detected with flow cytometry.

2.4. Quantitative Real-Time RT-PCR (qRT-PCR) Analysis. The detailed methodology was described in our previous study [22]. Briefly, total RNA was prepared with Trizol...
(Invitrogen, Carlsbad, USA), and cDNA was synthesized using a cDNA Synthesis Kit (Invitrogen). qRT-PCR was performed with the SYBR Green Master Mix (Tiangen, Beijing, China). The primers used were as follows: HIF-1α, forward primer 5′-TCACACAGGAGACAGTACAGATGC-3′ and reverse primer 5′-CCAGCAAGTTAAGCCATCAGGTCC-3′; VEGFA, forward primer 5′-AGGAGGCGAGATCATCAGCT-3′ and reverse primer 5′-CAAAGCCACA GGATTCTTTTCT-3′; and GAPDH, forward primer 5′-TTACTCCTTGGGAGCCATGTGGGC-3′ and reverse primer 5′-ACTGACCCAGAGACAGTGGATGG-3′.

2.5. Nucleoprotein Extraction and Western Blot Analysis. Subcellular fractionation was performed as per the manufacturer’s instructions (Thermo Scientific, San Jose, CA, USA). Protein concentrations of cellular or nuclear extracts were determined using a bicinchoninic acid (BCA) assay kit (Bio-Rad Laboratories, Inc.). In brief, equal amounts (20-25 μg) of protein fractions of lysate were resolved using SDS-polycrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membranes (Millipore, USA), and immunoblotted as previously described in our study [25].

2.6. Gene Transfection and RNAi. The method was described in our previous study [5]. Silencing of pVHL shRNA was acquired by way of lentiviral transduction of the following specific shRNA vectors, purchased from Santa Cruz Biotechnology: pVHL shRNA (sc-36816-V) and scramble shRNA control (sc-108080).

2.7. Statistical Analyses. The data were analyzed with SPSS software (version 21.0, Chicago, IL, USA) and expressed as the mean ± standard deviation (SD). Chi-squared, Kaplan-Meier, and Pearson’s correlation analyses were used to analyze TMA data. Student’s t-tests were used for comparisons between 2 groups, and one-way analysis of variance was used for comparisons between multiple groups. P < 0.05 was considered to indicate statistically significant results.

3. Results

3.1. Expression and Correlation between COX-2 and HIF-1α in HCC Specimens. We first examined expression of COX-2 and HIF-1α in HCC tissues in a TMA. As shown in Figure 1(a), the IHC staining of COX-2 and HIF-1α, with hematoxylin and eosin (HE), were classified as TNM1-IV. The clinicopathological distribution features of COX-2 are presented in Table 1. There was no significant correlation between COX-2 expression and clinicopathological variables including patient age, sex, histology grade, and lymph node metastasis (Table 1). The association between patient survival and COX-2 or HIF-1α expression was measured through the Kaplan-Meier analysis and log-rank test, respectively. The data demonstrated that compared with low expression of COX-2 or HIF-1α, the overall survival in HCC patients with high expression of COX-2 or HIF-1α has a downward trend (P = 0.002 and P = 0.007, respectively, Figure 1(b)).

The univariate Cox proportional hazards regression model was applied in order to evaluate the crude hazard ratios (HRs) of COX-2 expression or each clinicopathological variable on patient survival. According to the univariate Cox regression analyses, COX-2 expression was closely related to overall survival (P = 0.003, Table 2). Multivariate analysis was conducted, and the significant factors are summarized in Table 2 so as to further confirm the prognostic value of COX-2. Expression of COX-2 was an independent prognostic marker according to the Cox regression model. Moreover, a positive correlation between COX-2 expression and the level of HIF-1α was found in accordance with the results, regardless of nuclear or cytoplasmic localization (Pearson’s correlation, R2 = 0.061, P = 0.019, Figure 1(c)).

3.2. Meloxicam Exerts an Antitumor Effect under Hypoxic Conditions in 2 HCC Cell Lines. Meloxicam, a selective COX-2 inhibitor, exerts extensive antitumor effect on various malignant tumors [24, 25]. Therefore, in our study, it was hypothesized that meloxicam could inhibit HCC cell proliferation and angiogenesis, especially under hypoxic conditions. Huh-7 and Hep3B cells were exposed to meloxicam for 24 h under normoxic or hypoxic conditions, and cell proliferation was determined utilizing the CCK-8 and colony formation assay. As shown in Figure 2(a), meloxicam significantly inhibited cell viability under normoxic conditions and weakened the hypoxia-induced proliferation capability in both HCC cells. However, meloxicam only mildly affected the normal human liver cell line: L-02. The results of the colony formation assay were consistent with the cell viability assay. A notable increase induced by hypoxia in the clonogenic survival of HCC cells could be reversed by meloxicam (Figure 2(b)). Next, we investigated the effect of meloxicam on angiogenesis. Human umbilical vein endothelial cells (HUVECs) were incubated with or without meloxicam (80 μM) for 24 h under normoxic or hypoxic conditions. It was found that capillary-like tube formation was remarkably inhibited by meloxicam under hypoxic conditions (Figure 2(c)).

3.3. Meloxicam Overcomes Hypoxia-Induced Apoptotic Resistance Requiring Caspase Activities in HCC Cells. An analysis of the cell cycle and apoptosis of Huh-7 and Hep3B cells under hypoxic conditions was performed by flow cytometry (FACS). As shown in Figures 3(a) and 3(b), meloxicam markedly arrested both Huh-7 and Hep3B cells in the G1 phase and increased cellular apoptosis in a concentration-dependent manner. Caspase activation is considered one of the apoptosis mechanisms in COX-2 inhibitor-treated tumor cells [26]. In the present study, we used Western blot to detect expression of PARP1, caspase-3, and caspase-9 after Huh-7 and Hep3B cells were exposed to meloxicam under hypoxic conditions. As shown in Figure 3(c), meloxicam dose dependently decreased the level of full-length PARP1, procaspase-3, and procaspase-9 and strengthened the cleavage of PARP1, caspase-3, and caspase-9 in HCC cells. In addition, Z-VAD-FMK, a pancaspase inhibitor, notably decreased meloxicam-induced apoptosis (Figure 3(b)). During apoptosis, another important
Figure 1: COX-2 and HIF-1α expressions in HCC tissues. (a) IHC staining of COX-2 and HIF-1α and HE in HCC tissue (magnification ×200). (b) High COX-2 or HIF-1α expressions correlate with poorer overall survival ($P = 0.002$ and $P = 0.007$, respectively, log-rank test). (c) Positive correlation between COX-2 expression and HIF-1α level (Pearson’s correlation, $R^2 = 0.061$, $P = 0.019$).
Table 1: Correlation between COX-2 expression and clinicopathological characteristics of HCC patients.

<table>
<thead>
<tr>
<th>Variables</th>
<th>COX-2 expression</th>
<th>Total</th>
<th>$\chi^2$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
<td>High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (year)</td>
<td></td>
<td></td>
<td>0.729</td>
<td>0.393</td>
</tr>
<tr>
<td>$\leq$54</td>
<td>17</td>
<td>28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&gt;$54</td>
<td>21</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>0.178</td>
<td>0.673</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>32</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td>1.966</td>
<td>0.161</td>
</tr>
<tr>
<td>I/II</td>
<td>30</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>8</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td>5.024</td>
<td>0.025*</td>
</tr>
<tr>
<td>T1/T2</td>
<td>27</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3/T4</td>
<td>9</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>36</td>
<td>47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M stage</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>36</td>
<td>47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td>5.024</td>
<td>0.025*</td>
</tr>
<tr>
<td>I/II</td>
<td>27</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III/IV</td>
<td>9</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td>4.819</td>
<td>0.028*</td>
</tr>
<tr>
<td>$\leq$5 cm</td>
<td>22</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&gt;$5 cm</td>
<td>16</td>
<td>34</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Statistically significant ($P < 0.05$).

Table 2: Univariate and multivariate analyses of the factors correlated with overall survival of HCC patients.

<table>
<thead>
<tr>
<th>Variables</th>
<th>HR</th>
<th>95% CI</th>
<th>$P$ value</th>
<th>HR</th>
<th>95% CI</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expression</td>
<td>2.780</td>
<td>1.406-5.494</td>
<td>0.003*</td>
<td>2.373</td>
<td>1.101-5.112</td>
<td>0.027*</td>
</tr>
<tr>
<td>Sex</td>
<td>2.253</td>
<td>0.885-5.737</td>
<td>0.089</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td>2.034</td>
<td>1.158-3.572</td>
<td>0.013*</td>
<td>1.414</td>
<td>0.741-2.696</td>
<td>0.293</td>
</tr>
<tr>
<td>Age</td>
<td>0.985</td>
<td>0.954-1.018</td>
<td>0.366</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td>2.687</td>
<td>1.593-4.530</td>
<td>$\leq$0.001*</td>
<td>3.338</td>
<td>0.726-15.338</td>
<td>0.121</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M stage</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td>2.616</td>
<td>1.488-4.600</td>
<td>0.001*</td>
<td>0.449</td>
<td>0.079-2.559</td>
<td>0.367</td>
</tr>
<tr>
<td>Tumor size</td>
<td>1.085</td>
<td>1.036-1.137</td>
<td>0.001*</td>
<td>1.044</td>
<td>0.967-1.128</td>
<td>0.269</td>
</tr>
</tbody>
</table>

*Statistically significant ($P < 0.05$).
intracellular event is the occurrence of the disruption of mitochondrial membrane potential ($\Delta \Psi_m$). We found, by JC-1 analysis, that meloxicam notably weakened $\Delta \Psi_m$ in both HCC cells, which suggested that meloxicam causes disruption of $\Delta \Psi_m$, thereby triggering caspase-dependent apoptosis (Figure 3(d)).

3.4. Meloxicam Downregulates HIF-1α Transcription Activity and Expression in a VHL-Dependent Manner. Accumulated evidence has demonstrated that HIF-1α has a dominant role in tumor progression, and HIF-1α-regulation of expression of VEGFA is regarded as the main inducer of angiogenesis [27–29]. In the current study, we hypothesized if meloxicam...
Figure 3: Meloxicam induces caspase-dependent apoptosis in human HCC cells under hypoxic conditions. (a, b) Cells were treated with meloxicam (0 to 80 μM) or meloxicam (80 μM)+Z-VAD-FMK (50 μM) under hypoxic conditions for 24 h. The cell cycle and apoptosis were analyzed by FACS flow cytometry. *P < 0.05 and **P < 0.01 vs. control. (c) Protein levels of PARP1, caspase-3, and caspase-9 were detected by Western blot analysis. Levels of GAPDH served as a loading control. (d) Disruption of mitochondrial membrane potential (∆ψm) was determined by JC-1 analysis. **P < 0.01 vs. control. Data are presented as means ± SD of three independent experiments.
Figure 4: Continued.
could inhibit HIF-1α expression and its target gene VEGFA. To answer this question, the two HCC cell lines were treated with meloxicam (0 to 80 μM) for 24 h under hypoxic conditions. It was found that meloxicam significantly decreased the level of HIF-1α and VEGFA protein expression compared to the control group (Figure 4(a)). To investigate whether meloxicam could inhibit the transcriptional activity of HIF-1α in Huh-7 and Hep3B cells, a hypoxia-responsive reporter including a luciferase gene with a hypoxia response element (HRE) was introduced. As shown in Figure 4(b), the HIF-1α transcriptional activities of Huh-7 and Hep3B cells exposed to meloxicam were both weakened under hypoxic conditions. qRT-PCR results indicated that the extent of VEGFA mRNA was also suppressed when treated with meloxicam. However, interestingly, it was found that incubation with meloxicam did not attenuate the extent of HIF-1α mRNA, which suggested that meloxicam may regulate HIF-1α at posttranscriptional levels but not at the transcriptional level (Figure 4(c)).

As a negative regulator of HIF-1α, pVHL has an important role in cellular oxygen sensing through ubiquitination and subsequent proteasomal degradation [7]. The loss of pVHL results in the accumulation and translocation of HIF-α into the nucleus, which subsequently activates the transcription of HIF target genes to participate in important oncogenic pathways, such as angiogenesis [30, 31]. Here, we explored whether meloxicam was involved in the process of HIF-1α degradation through pVHL upregulation. As shown in Figure 4(a), meloxicam notably upregulated the expression of pVHL in a concentration-dependent manner. To further ascertain the effect of pVHL in meloxicam-regulated suppression of HIF-1α, a lentivirus-mediated pVHL shRNA to knock down pVHL was introduced in Huh-7 and Hep3B cell lines which were defined as Huh-7-pVHL shRNA cell and Hep3B-pVHL shRNA cell, respectively. Western blot results showed that pVHL silencing could attenuate the suppression of HIF-1α by meloxicam, which suggested that meloxicam downregulates HIF-1α signaling by augmenting pVHL expression under hypoxic conditions (Figures 4(d) and 4(e)).

3.5. Meloxicam Attenuates HIF-1α Nuclear Translocation and Promotes the Proteasomal Degradation of HIF-1α. The effect of meloxicam in significantly decreasing HIF-1α transcriptional activity urged us to further investigate whether meloxicam could affect HIF-1α’s subcellular localization for hypoxia-induced nuclear translocation protecting HIF-1α against downregulation by way of pVHL as previously reported [32]. Western blotting results revealed that meloxicam repressed the nuclear localization of HIF-1α compared with empty vector controls in both Huh-7-pVHL shRNA and Hep3B-pVHL shRNA cell lines (Figure 5(a)). In order to further confirm the effect of meloxicam on reducing HIF-1α’s nuclear accumulation and sequestering it in the cytoplasm, immunofluorescent (IF) staining was utilized and the results showed that meloxicam treatment altered the nuclear localization of HIF-1α in Huh-7-pVHL shRNA and Hep3B-pVHL shRNA cell lines whose cytosolic localization was increased and nuclear accumulation was suppressed under hypoxic conditions (Figure 5(b)). Based on these findings, we are eager to further explore the mechanisms through which meloxicam downregulates HIF-1α. Proteasomal degradation plays a crucial role in cellular protein turnover [33, 34]. Cycloheximide (CHX) is an antifungal antibiotic that inhibits protein synthesis in eukaryotes. Here, we used CHX to inhibit de novo protein synthesis in Huh-7 and Hep3B cell lines. In this way, changes in the expression of HIF-1α will mainly reflect its protein degradation. We found that the intensity of HIF-1α in the presence of CHX was dramatically diminished by meloxicam treatment which implied that meloxicam may be involved in the degradation of HIF-1α (Figure 5(c)). Next, we utilized a specific proteasome inhibitor, MG132, to further test the hypothesis that meloxicam targets HIF-1α for proteasomal degradation. It was found that MG132 treatment in the presence of meloxicam
suppressed downregulation of HIF-1α which revealed that meloxicam could induce HIF-1α proteasomal degradation in a hypoxic environment (Figure 5(d)).

3.6. Meloxicam Arrests Tumor Growth and Angiogenesis In Vivo. Considering meloxicam’s superior antitumor effects in vitro, we investigated whether meloxicam could inhibit...
**Figure 6: Continued.**

(a) Tumor volume (mm³) over time for Huh-7 and Hep3B cells treated with control or meloxicam. The graph shows a significant reduction in tumor volume in the meloxicam-treated groups compared to the control groups. Asterisks indicate statistical significance.

(b) Immunohistochemical staining for HIF-1α, CD31, Ki-67, and TUNEL in Huh-7 and Hep3B cells. The staining patterns highlight differences in cell proliferation and apoptosis between control and meloxicam-treated samples.
tumor development in vivo. As shown in Figure 6(a), meloxicam notably suppressed growth of Huh-7 and Hep3B xenograft tumors. Next, HIF-1α as well as hallmarks of growth and angiogenesis was detected by IHC and IF analysis, which revealed downregulation in HIF-1α, Ki-67, and CD31 in tumor tissues treated with meloxicam, whereas TUNEL staining showed opposite results (Figure 6(b)). The result of IF analysis revealed the suppression of expression of VEGFA in meloxicam-treated groups (Figure 6(c)). The data of Western blot showed that meloxicam treatment remarkably blocked the level of HIF-1α and VEGFA, while enhancing pVHL expression in Huh-7 and Hep3B cell-derived tumors (Figure 6(d)).

4. Discussion

Given that hypoxic HCC cells are proangiogenic and anti-apoptotic and that the HIF-1α signaling pathway has a crucial role in regulating cellular adaptation to hypoxia, our study investigated responses of Huh-7 and Hep3B cell lines to meloxicam, a COX-2-selective inhibitor, which has been considered a potential candidate for targeting the HIF-1α-VEGF axis [15], and investigated the potential mechanism involved in regulating these responses. The present study initially utilized TMA technology and IHC to explore expression of COX-2 and HIF-1α in HCC. The data indicated a positive correlation between COX-2 and COX-2 or HIF-1α expression in connection with poor prognosis in HCC patients. In the in vitro experiment, it was demonstrated that meloxicam not only suppressed cell growth and angiogenesis but also caused disturbance of mitochondrial membrane potential (ΔΨm), leading to caspase-dependent apoptosis under hypoxia. However, there was no significant cytotoxicity in normal human liver cell lines treated with meloxicam. We also found that meloxicam
had the ability of inhibiting tumor growth in subcutaneous HCC mouse models in vivo.

In previous studies, it was found that HIF-1α was notably stabilized in malignant tumor cells under hypoxic conditions, along with upregulating its target gene, VEGFA, which is considered the principal inducer of angiogenesis [35]. This current study showed that both the protein levels of HIF-1α and VEGFA were decreased when treated with meloxicam. But qRT-PCR analysis showed that the extent of HIF-1α was only mildly changed after being exposed to meloxicam. To investigate whether meloxicam could affect the transcriptional activity of HIF-1α, a reporter plasmid was introduced and the results revealed that meloxicam treatment results in reduced HIF-1α transcription activity. These data implied that meloxicam decreased HIF-1α’s transcription activity but not via its transcriptional level and therefore, meloxicam may be a post-transcriptional regulator of HIF-1α. Moreover, the level of HIF-1α in the presence of CHX, an inhibitor of protein synthesis, was significantly reduced by meloxicam treatment. MG132, which is a proteasomal inhibitor, exposed to meloxicam prevented the degradation of HIF-1α. These data revealed that meloxicam treatment alters the nuclear localization of HIF-1α and promotes its degradation. Therefore, we thought an important possibility that might explain the mechanisms of inhibition of tumor growth is that HIF-1α cytoplasmic-nuclear trafficking and proteasomal degradation by meloxicam could counteract hypoxia-regulated drug resistance.

Previous studies reported that the pVHL is one of the negative regulators of the HIF transcription factor [36–38]. Thus, modulating the extent of pVHL expression under hypoxic conditions may offer an effective therapy for HCC. The current work indicated that meloxicam inhibits the HIF-1α signaling pathway and reduces its target gene VEGFA both in vitro and in vivo whereas VHL silencing suppresses meloxicam-mediated HIF-1α downregulation. In conclusion, our results provide direct and strong evidence that the HIF-1α signals in HCC. These data provide strong evidence that the COX-2-specific inhibitor exhibits promising potential for the treatment of HCC, but further clinical investigation is still required.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest

The authors declare no potential conflicts of interest.

Authors’ Contributions

Yinghong Zhou and Xiaofeng Dong have contributed equally to this work.

Acknowledgments

We thank Dr. Edward C. Mignot, Shandong University, for linguistic advice. We also thank all members of the Research Center of Medical Sciences for the support and discussions. This research was supported by the National Natural Science Foundation of China (grant nos. 81802458, 81560406, and 81802414) and the Youth Startup Foundation of the Shandong Cancer Hospital (grant no. 2018qn022).

References


